#Germany #Fremont #Alamar Biosciences #Proteomics #DZNE

Alamar Biosciences Partners with DZNE for Revolutionary Study on Neurodegenerative Diseases

In a major advancement in the field of biomedical research, Alamar Biosciences has established a strategic collaboration with the German Centre for Neurodegenerative Diseases (DZNE). Together, they aim to pioneer a comprehensive proteomic profiling study within the Rhineland Study cohort, which represents one of the most ambitious longitudinal studies focused on aging and neurodegenerative diseases worldwide.

Objectives of the Study

The primary goal of this partnership is to deploy Alamar's ultra-sensitive diagnostic panels, specifically the NULISAseq™ CNS Disease Panel 120 and the Inflammation Panel 250, across a vast dataset of 23,000 longitudinal plasma samples collected from the Rhineland Study. This initiative seeks to accelerate the discovery of essential biomarkers indicative of healthy aging and neurodegeneration. As Professor Monique Breteler, the director of population health sciences at DZNE, articulated, understanding aging and dementia involves employing advanced technologies and well-characterized cohorts.

What Makes NULISAseq Unique?

Alamar's NULISAseq platform represents the forefront of precision proteomics, capable of detecting minute quantities of proteins linked to brain health, thus showcasing unmatched sensitivity and specificity. For instance, the CNS Disease Panel is equipped to distinguish between phosphorylated tau protein derived from the brain and the total phosphorylated tau in plasma, marking a significant milestone for early detection and risk stratification of neurodegenerative conditions like Alzheimer’s disease.

Moreover, the Inflammation Panel 250 offers the most extensive and sensitive profiling of immune-related proteins associated with neuroinflammation and aging, further enhancing our understanding of these complex interactions.

Integration with Clinical and Imaging Data

The proteomic data generated through this study will be diligently integrated with extensive clinical, demographic, and imaging datasets from the Rhineland Study. This integration is designed to allow researchers to track protein evolution over time, thereby identifying early biomarkers that could lead to precision diagnostics and targeted therapeutic strategies.

Dr. Yuling Luo, the founder and CEO of Alamar Biosciences, emphasized the importance of this collaboration, stating it signifies a monumental leap in dementia and aging research. He noted that through the unparalleled sensitivity of the NULISA technology and the extensive reach of the DZNE Rhineland Study, novel protein biomarkers could be unearthed to better illustrate cognitive health trajectories and disease progression within aging populations.

Significance and Future Directions

This partnership underscores a shared commitment to advancing scientific rigor, inclusivity, and innovation in neurodegenerative disease research. By unraveling diverse aging trajectories within a deeply characterized population, Alamar and DZNE aim to achieve earlier diagnostics, superior prognostics, and innovative therapeutic pathways for age-related brain disorders.

About the Rhineland Study

The DZNE's Rhineland Study is a large-scale population-based cohort that tracks thousands of individuals over decades to uncover the determinants of healthy aging and neurodegeneration. It collects detailed clinical data, imaging, genetic information, and lifestyle data, which are harmonized to provide a holistic understanding of the aging brain. For more information, visit DZNE and Rhineland Study.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company dedicated to developing precision proteomics for early disease detection. With its proprietary NULISA platform and ARGO HT system, the company leverages the latest advancements in genomics to achieve unmatched attomolar detection sensitivity, surpassing existing protein detection technologies. Learn more at alamarbio.com.